. Author manuscript; available in PMC: 2014 Apr 1.

Published in final edited form as: Arthritis Care Res (Hoboken). 2013 Apr;65(4):578–584. doi: 10.1002/acr.21817

Table 5.

Baseline characteristics of allopurinol initiators who developed severe cutaneous adverse reactions (SCARs) vs. those who did not.

	SCARs (N= 45)	No SCARs (N= 90,313)
Demographic characteristics
Age (year), mean (SD)	73.7 (11.8)	65.5 (15.6)
Male, n (%)	11 (24.4)	47,267 (52.3)
White, n (%)	11 (24.4)	37,392 (41.4)

Health care utilization
No. of outpatient visit, mean (SD)	43.1 (45.8)	27.0 (32.4)
1 or more ER visits, n (%)	22 (48.9)	32,805 (36.3)
No. of all prescription drugs, mean (SD)	8.5 (4.1)	6.9 (4.9)
1 or more hospitalization, n (%)	22 (48.9)	22,897 (25.4)

Comorbidities
Comorbidity Index, mean (SD)	3.0 (1.8)	1.9 (2.1)
Diabetes mellitus, n (%)	11 (24.4)	16,931 (18.8)
Hypertension, n (%)	23 (51.1)	29,396 (32.6)
Heart failure, n (%)	11 (24.4)	12,198 (13.5)

SD: standard deviation, ER: emergency room,